Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers.
Target Price
The average target price of LUNG is 5.6 and suggests 120% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell